Division of Plastic Surgery, Albany Medical Center, Albany.
Division of Plastic and Reconstructive Surgery, Montefiore Medical Center, Bronx, NY.
J Craniofac Surg. 2021 Sep 1;32(6):2176-2179. doi: 10.1097/SCS.0000000000007629.
Traumatic orbital apex syndrome (TOAS) commonly occurs secondary to trauma and irreversible ischemic optic neuropathy occurs as early as 2 hours after injury. Multiple treatment options have been described, however, there is a lack of consensus regarding the optimal treatment of these patients.
A systematic review of the PubMed Database from 1970 to 2020 was conducted, using the search terms "orbital apex," "syndrome," and "traumatic" with the Boolean operators "AND" or "OR." Papers that did not describe TOAS, describe patient outcomes or treatments, and those without available full English text were excluded. Patients were clustered and compared based on treatment received with the primary outcomes of improvement in vision or ophthalmoplegia.
Three hundred forty-seven papers were identified, of which 22 were included, representing 117 patients with TOAS. A total of 75.9% patients underwent decompressive surgery, 82.6% received steroids, and 72.2% received nerve growth factors. Fewer than 20% of patients were treated with antibiotics, diuretics, hormones, or hyperbaric oxygen. Overall, 51.7% of patients experienced improvement in vision and 85.2% in ophthalmoplegia at 6 months. Patients treated with surgical decompression (66.7% versus 16.7%, P < 0.01) or steroids (60.0% versus 0%; P < 0.01) were more likely to have improvement in vision than those without treatment. Nerve growth factors did not improve vision. Ophthalmoplegia did not improve with any treatment.
Outcomes of TOAS tend to be poor, with overall low recovery of vision, though surgical decompression or steroid treatment did suggest improved visual outcomes. Further standardized patient data is needed to elucidate the comparative effectiveness of these interventions.
创伤性眶尖综合征(TOAS)通常继发于创伤,伤后 2 小时即可发生不可逆性缺血性视神经病变。已经描述了多种治疗选择,但是对于这些患者的最佳治疗方法还没有达成共识。
对 1970 年至 2020 年的 PubMed 数据库进行了系统回顾,使用的检索词是“眶尖”“综合征”和“创伤性”,并使用布尔运算符“AND”或“OR”。排除了未描述 TOAS、未描述患者结局或治疗方法以及没有英文全文的论文。根据所接受的治疗,将患者分组并进行比较,主要结局是视力或眼肌麻痹的改善。
共确定了 347 篇论文,其中 22 篇被纳入,共涉及 117 例 TOAS 患者。共有 75.9%的患者接受了减压手术,82.6%的患者接受了皮质类固醇治疗,72.2%的患者接受了神经生长因子治疗。不到 20%的患者接受了抗生素、利尿剂、激素或高压氧治疗。总体而言,51.7%的患者在 6 个月时视力改善,85.2%的患者眼肌麻痹改善。接受手术减压(66.7%比 16.7%,P<0.01)或皮质类固醇(60.0%比 0%;P<0.01)治疗的患者视力改善的可能性高于未接受治疗的患者。神经生长因子并不能改善视力。任何治疗都不能改善眼肌麻痹。
TOAS 的结局往往较差,总体视力恢复较低,但手术减压或皮质类固醇治疗确实提示了更好的视力结局。需要进一步标准化患者数据,以阐明这些干预措施的相对有效性。